Portal de Periódicos da CAPES

RNA splicing factors as oncoproteins and tumour suppressors

2016; Nature Portfolio; Volume: 16; Issue: 7 Linguagem: Inglês

10.1038/nrc.2016.51

1474-1768

Heidi Dvinge, Eun Hee Kim, Omar Abdel‐Wahab, Robert K. Bradley,

RNA and protein synthesis mechanisms

This Review discusses the current genetic and functional links between dysregulated and/or mutated RNA splicing factors and cancer, as well as the therapeutic opportunities presented by alterations in alternative splicing in cancer. The recent genomic characterization of cancers has revealed recurrent somatic point mutations and copy number changes affecting genes encoding RNA splicing factors. Initial studies of these 'spliceosomal mutations' suggest that the proteins bearing these mutations exhibit altered splice site and/or exon recognition preferences relative to their wild-type counterparts, resulting in cancer-specific mis-splicing. Such changes in the splicing machinery may create novel vulnerabilities in cancer cells that can be therapeutically exploited using compounds that can influence the splicing process. Further studies to dissect the biochemical, genomic and biological effects of spliceosomal mutations are crucial for the development of cancer therapies targeted at these mutations.